| Trial ID: | L4947 |
| Source ID: | NCT04667143
|
| Associated Drug: |
Retagliptin, Henagliflozein, Metformin Xr
|
| Title: |
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type II
|
| Interventions: |
DRUG: Retagliptin, Henagliflozein, metformin XR
|
| Outcome Measures: |
Primary: Mean change from baseline in HbA1c at Week 24, • To compare the mean change from baseline in HbA1c achieved with concurrent addition of Retagliptin Plus Henagliflozein to metformin vs the addition of Retagliptin or Henagliflozein to metformin after 24 weeks of double-blind treatment., 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
760
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2021-01
|
| Completion Date: |
2022-10
|
| Results First Posted: |
|
| Last Update Posted: |
2020-12-14
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT04667143
|
